Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbc.com)